Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials

References

• Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788.
   PubMed Web of Science ®Google Scholar
• Shaw TD, McAuley DF, O’Kane CM. Emerging drugs for treating the acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2019;24(1):29–41.
   PubMed Web of Science ®Google Scholar
• Bos LDJ, Artigas A, Constantin J-M, et al., Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research. Eur Respir Rev. 2021;30(159):200317.
   PubMed Web of Science ®Google Scholar
• Goligher EC, Ranieri VM, Slutsky AS. Is severe COVID-19 pneumonia a typical or atypical form of ARDS? And does it matter? Intensive Care Med. 2021;47(1):83–85.
   PubMed Web of Science ®Google Scholar
• Rezoagli E, Fumagalli R, Bellani G. Definition and epidemiology of acute respiratory distress syndrome. Ann Transl Med. 2017;5(14):282.
   PubMed Web of Science ®Google Scholar
• Laffey JG, Bellani G, Pham T, et al. Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study. Intensive Care Med. 2016;42(12):1865–1876.
   PubMed Web of Science ®Google Scholar
• Brower R, Matthay M, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301–1308.
   PubMed Web of Science ®Google Scholar
• Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351:327–336.
   PubMed Web of Science ®Google Scholar
• Amato MBP, Meade MO, Slutsky AS, et al. driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372(8):747–755.
   PubMed Web of Science ®Google Scholar
• Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome. JAMA. 2010;303(9):865.
   PubMed Web of Science ®Google Scholar
• Sakr Y, Vincent J-L, Reinhart K, et al. High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest. 2005;128(5):3098–3108.
   PubMed Web of Science ®Google Scholar
• Matthay MA, McAuley DF, Ware LB. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med. 2017;5(6):524–534.
   PubMed Web of Science ®Google Scholar
• Cochi SE, Kempker JA, Annangi S, et al. Mortality trends of acute respiratory distress syndrome in the United States from 1999-2013. Ann Am Thorac Soc. 2016;13(10):1742–1751.
   PubMed Web of Science ®Google Scholar
• Sweeney RM, McAuley DF. Acute respiratory distress syndrome. Lancet. 2016;388(10058):2416–2430.
   PubMed Web of Science ®Google Scholar
• Battaglini D, Sottano M, Ball L, et al. Ten golden rules for individualized mechanical ventilation in acute respiratory distress syndrome. J Intensive Med. 2021;1(1):42–51.
   Google Scholar
• Slutsky AS. History of mechanical ventilation. from vesalius to ventilator-induced lung injury. Am J Respir Crit Care Med. 2015;191(10):1106–1115.
   PubMed Web of Science ®Google Scholar
• Walkey AJ, Goligher EC, Del Sorbo L, et al. Low tidal volume versus non–volume-limited strategies for patients with acute respiratory distress syndrome. A systematic review and meta-analysis. Ann Am Thorac Soc. 2017;14(Supplement_4):S271–S279.
   PubMedGoogle Scholar
• Goligher EC, Kavanagh BP, Rubenfeld GD, et al. Oxygenation response to positive end-expiratory pressure predicts mortality in acute respiratory distress syndrome. A secondary analysis of the LOVS and express trials. Am J Respir Crit Care Med. 2014;190(1):70–76.
   PubMed Web of Science ®Google Scholar
• Mercat A, Richard J-CM, Vielle B, et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome. JAMA. 2008;299(6):646.
   PubMed Web of Science ®Google Scholar
• Meade MO, Cook DJ, Guyatt GH, et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome. JAMA. 2008;299(6):637.
   PubMed Web of Science ®Google Scholar
• Ball L, Serpa Neto A, Trifiletti V, et al. Effects of higher PEEP and recruitment manoeuvres on mortality in patients with ARDS: a systematic review, meta-analysis, meta-regression and trial sequential analysis of randomized controlled trials. Intensive Care Med Exp. 2020;8(S1):39.
   PubMedGoogle Scholar
• Cavalcanti AB, Suzumura ÉA, Laranjeira LN, et al. Effect of lung recruitment and titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on mortality in patients with acute respiratory distress syndrome. JAMA. 2017;318(14):1335.
   PubMed Web of Science ®Google Scholar
• Hodgson CL, Cooper DJ, Arabi Y, et al. Maximal recruitment open lung ventilation in acute respiratory distress syndrome (PHARLAP). A Phase II, multicenter randomized controlled clinical trial. Am J Respir Crit Care Med. 2019;200(11):1363–1372.
   PubMed Web of Science ®Google Scholar
• Papazian L, Aubron C, Brochard L, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):69.
   PubMedGoogle Scholar
• Dianti J, Tisminetzky M, Ferreyro BL, et al. Association of PEEP and lung recruitment selection strategies with mortality in acute respiratory distress syndrome: a systematic review and network meta-analysis. Am J Respir Crit Care Med. 2022;205(11):1300–1310.
   PubMed Web of Science ®Google Scholar
• Amato MBP, Barbas CSV, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998;338(6):347–354.
   PubMed Web of Science ®Google Scholar
• Aoyama H, Pettenuzzo T, Aoyama K, et al. Association of driving pressure with mortality among ventilated patients with acute respiratory distress syndrome. Crit Care Med. 2018;46(2):300–306.
   PubMed Web of Science ®Google Scholar
• Mahmoud O. Mechanical power is associated with increased mortality and worsened oxygenation in ARDS. Chest. 2020;158(4):A679.
   Web of Science ®Google Scholar
• Serpa Neto A, Deliberato RO, Johnson AEW, et al. Mechanical power of ventilation is associated with mortality in critically ill patients: an analysis of patients in two observational cohorts. Intensive Care Med. 2018;44(11):1914–1922.
   PubMed Web of Science ®Google Scholar
• Grieco DL, Costa ELV, Nolan JP. The importance of ventilator settings and respiratory mechanics in patients resuscitated from cardiac arrest. Intensive Care Med. 2022;48(8):1056–1058.
   PubMed Web of Science ®Google Scholar
• Robba C, Badenes R, Battaglini D, et al. Ventilatory settings in the initial 72 h and their association with outcome in out-of-hospital cardiac arrest patients: a preplanned secondary analysis of the targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest (TTM2) tr. Intensive Care Med. 2022;48(8):1024–1038.
   PubMed Web of Science ®Google Scholar
• Murray MJ, DeBlock H, Erstad B, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2016;44(11):2079–2103.
   PubMed Web of Science ®Google Scholar
• Guérin C, Reignier J, Richard J-C, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–2168.
   PubMed Web of Science ®Google Scholar
• Moss M, Huang D, Brower R, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380:1997–2008.
   PubMed Web of Science ®Google Scholar
• Alhazzani W, Alshahrani M, Jaeschke R, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2013;17(2):R43.
   PubMed Web of Science ®Google Scholar
• Atn H, Patolia S, Guervilly C. Neuromuscular blockade in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. J Intensive Care. 2020;8(1):12.
   PubMed Web of Science ®Google Scholar
• Wiedemann H, Wheeler A, Bernard G, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564–2575.
   PubMed Web of Science ®Google Scholar
• Carvalho NC, Güldner A, Beda A, et al. Higher levels of spontaneous breathing reduce lung injury in experimental moderate acute respiratory distress syndrome. Crit Care Med. 2014;42(11):e702–e715.
   PubMed Web of Science ®Google Scholar
• Chanques G, Constantin J-M, Devlin JW, et al. Analgesia and sedation in patients with ARDS. Intensive Care Med. 2020;46(12):2342–2356.
   PubMed Web of Science ®Google Scholar
• Tarazan N, Alshehri M, Sharif S, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta-analysis of randomized trials. Intensive Care Med Exp. 2020;8(1):61.
   PubMed Web of Science ®Google Scholar
• Papazian L, Forel J-M, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107–1116.
   PubMed Web of Science ®Google Scholar
• Fanelli V, Morita Y, Cappello P, et al. Neuromuscular blocking agent cisatracurium attenuates lung injury by inhibition of nicotinic acetylcholine receptor-α1. Anesthesiology. 2016;124(1):132–140.
   PubMed Web of Science ®Google Scholar
• Forel J-M, Roch A, Marin V, et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2006;34(11):2749–2757.
   PubMed Web of Science ®Google Scholar
• Alhazzani W, Belley-Cote E, Møller MH, et al. Neuromuscular blockade in patients with ARDS: a rapid practice guideline. Intensive Care Med. 2020;46(11):1977–1986.
   PubMed Web of Science ®Google Scholar
• Maca J, Jor O, Holub M, et al. Past and present ARDS mortality rates: a systematic review. Respir Care. 2017;62(1):113–122.
   PubMed Web of Science ®Google Scholar
• Fröhlich S, Murphy N, Boylan JF. ARDS: progress unlikely with non-biological definition. Br J Anaesth. 2013;111(5):696–699.
   PubMed Web of Science ®Google Scholar
• Boucher PE, Taplin J, Clement F. The Cost of ARDS. Chest. 2021;S0012-3692:03829.
   Google Scholar
• Bice T, Cox C, Carson S. Cost and health care utilization in ARDS—different from other critical illness? Semin Respir Crit Care Med. 2013;34(4):529–536.
   PubMed Web of Science ®Google Scholar
• Biehl M, Ahmed A, Kashyap R, et al. The incremental burden of acute respiratory distress syndrome: long-term follow-up of a population-based nested case-control study. Mayo Clin Proc. 2018;93(4):445–452.
   PubMed Web of Science ®Google Scholar
• Hussey PS, Schneider EC, Rudin RS, et al. Continuity and the costs of care for chronic disease. JAMA Intern Med. 2014;174(5):742.
   PubMed Web of Science ®Google Scholar
• Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017;377(6):562–572.
   PubMed Web of Science ®Google Scholar
• Rocco PRM, Negri EM, Kurtz PM, et al. Lung tissue mechanics and extracellular matrix remodeling in acute lung injury. Am J Respir Crit Care Med. 2001;164(6):1067–1071.
   PubMed Web of Science ®Google Scholar
• Pelosi P, Rocco PR. Effects of mechanical ventilation on the extracellular matrix. Intensive Care Med. 2008;34(4):631–639.
   PubMed Web of Science ®Google Scholar
• Aublanc M, Perinel S, Guérin C. Acute respiratory distress syndrome mimics. Curr Opin Crit Care. 2017;23(1):24–29.
   PubMed Web of Science ®Google Scholar
• Pelosi P, D’Onofrio D, Chiumello D, et al. Pulmonary and extrapulmonary acute respiratory distress syndrome are different. Eur Respir J. 2003;22(Supplement 42):48s–56s.
   Web of Science ®Google Scholar
• Gibelin A, Parrot A, Maitre B, et al. Acute respiratory distress syndrome mimickers lacking common risk factors of the Berlin definition. Intensive Care Med. 2016;42(2):164–172.
   PubMed Web of Science ®Google Scholar
• Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611–620.
   PubMed Web of Science ®Google Scholar
• Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195(3):331–338.
   PubMed Web of Science ®Google Scholar
• Sinha P, Delucchi KL, Thompson BT, et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. 2018;44(11):1859–1869.
   PubMed Web of Science ®Google Scholar
• Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018;6(9):691–698.
   PubMed Web of Science ®Google Scholar
• Delucchi K, Famous KR, Ware LB, et al. Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax. 2018;73(5):439–445.
   PubMed Web of Science ®Google Scholar
• Pelosi P, Ball L, Barbas CSV, et al., Personalized mechanical ventilation in acute respiratory distress syndrome. Crit Care. 2021;25(1):250.
   PubMed Web of Science ®Google Scholar
• Ball L, Silva PL, Rocco PRM, et al. A critical approach to personalised medicine in ARDS. Lancet Respir Med. 2020;8(3):218–219.
   PubMed Web of Science ®Google Scholar
• Reilly J, Calfee C, Christie J. Acute respiratory distress syndrome phenotypes. Semin Respir Crit Care Med. 2019;40(1):019–030.
   PubMed Web of Science ®Google Scholar
• Wilson JG, Calfee CS. ARDS subphenotypes: understanding a heterogeneous syndrome. Crit Care. 2020;24(1):102.
   PubMed Web of Science ®Google Scholar
• García-Laorden MI, Lorente JA, Flores C, et al. Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise. Ann Transl Med. 2017;5(14):283.
   PubMed Web of Science ®Google Scholar
• Acosta-Herrera M, Pino-Yanes M, Perez-Mendez L, et al. Assessing the quality of studies supporting genetic susceptibility and outcomes of ARDS. Front Genet. 2014;5:20.
   PubMed Web of Science ®Google Scholar
• Christie JD, Wurfel MM, Feng R, et al. Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma. checkley W, editor. PLoS One. 2012;7(1):e28268.
   PubMed Web of Science ®Google Scholar
• Cobb JP, O’Keefe GE. Injury research in the genomic era. Lancet. 2004;363(9426):2076–2083.
   PubMed Web of Science ®Google Scholar
• Villar J, Maca-Meyer N, Pérez-Méndez L, et al. Bench-to-bedside review: understanding genetic predisposition to sepsis. Crit Care. 2004;8(3):180–189.
   PubMed Web of Science ®Google Scholar
• Cardinal-Fernández P, Ferruelo A, El-Assar M, et al. Genetic predisposition to acute respiratory distress syndrome in patients with severe sepsis. Shock. 2013;39(3):255–260.
   PubMed Web of Science ®Google Scholar
• Shyamsundar M, McAuley DF, Ingram RJ, et al. Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury. Am J Respir Crit Care Med. 2014;189(12):1520–1529.
   PubMed Web of Science ®Google Scholar
• McAuley DF, Cross LM, Hamid U, et al. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respir Med. 2017;5(6):484–491.
   PubMed Web of Science ®Google Scholar
• Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154–162.
   PubMed Web of Science ®Google Scholar
• Sinha P, Delucchi KL, McAuley DF, et al., Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020;8(3):247–257.
   PubMed Web of Science ®Google Scholar
• Horie S, McNicholas B, Rezoagli E, et al., Emerging pharmacological therapies for ARDS: COVID-19 and beyond. Intensive Care Med. 2020;46(12):2265–2283.
   PubMed Web of Science ®Google Scholar
• Lin P, Zhao Y, Li X, et al. Decreased mortality in acute respiratory distress syndrome patients treated with corticosteroids: an updated meta-analysis of randomized clinical trials with trial sequential analysis. Crit Care. 2021;25(1):122.
   PubMed Web of Science ®Google Scholar
• Bernard G, Luce J, Sprung C, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Eng J Med. 1987;317(25):1565–1570.
   PubMed Web of Science ®Google Scholar
• Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. JAMA. 1998;280(2):159.
   PubMed Web of Science ®Google Scholar
• Annane D, Sébille V, Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 2006;34(1):22–30.
   PubMed Web of Science ®Google Scholar
• Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS. Chest. 2007;131(4):954–963.
   PubMed Web of Science ®Google Scholar
• Liu L, Li J, Huang Y, et al. The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness-related corticosteroid insufficiency. Zhonghua nei ke za zhi. 2012;51(8):599–603.
   PubMedGoogle Scholar
• Zhao W, Wan S, Gu D, et al. Therapeutic effect of glucocorticoid inhalation for pulmonary fibrosis in ARDS patients. Jie Fang Jun Yi Xue Za Zhi. 2014;39:741–745.
   Google Scholar
• Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20(1):329.
   PubMedGoogle Scholar
• Mohamed H, Meguid MA. Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/acute respiratory distress syndrome: randomized controlled study. Saudi J Anaesth. 2017;11(1):9.
   PubMed Web of Science ®Google Scholar
• Rezk NA, Ibrahim AM. Effects of methyl prednisolone in early ARDS. Egypt J Chest Dis Tuberc. 2013;62(1):167–172.
   Google Scholar
• Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–276.
   PubMed Web of Science ®Google Scholar
• Steinberg K, Hudson L, Goodman R, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354:1671–1684.
   PubMed Web of Science ®Google Scholar
• Weg J, Balk R, Tharratt R, et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA. 1994;272(18):1433–1438.
   PubMed Web of Science ®Google Scholar
• Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med. 1996;334(22):1417–1422.
   PubMed Web of Science ®Google Scholar
• Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1997;155(4):1309–1315.
   PubMed Web of Science ®Google Scholar
• Kesecioglu J, Schultz M, Lundberg D, et al. Treatment of acute lung injury (ALI/ARDS) with surfactant. Am J Respir Crit Care Med. 2001;163:A819.
   Web of Science ®Google Scholar
• Walmrath D, Grimminger F, Pappert D, et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J. 2002;19(5):805–810.
   PubMed Web of Science ®Google Scholar
• Spragg RG, Lewis JF, Wurst W, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med. 2003;167(11):1562–1566.
   PubMed Web of Science ®Google Scholar
• Spragg RG, Lewis JF, Walmrath H-D, et al. Effect of recombinant surfactant protein C–based surfactant on the acute respiratory distress syndrome. N Engl J Med. 2004;351(9):884–892.
   PubMed Web of Science ®Google Scholar
• Tsangaris I, Galiatsou E, Kostanti E, et al. The effect of exogenous surfactant in patients with lung contusions and acute lung injury. Intensive Care Med. 2007;33(5):851.
   PubMed Web of Science ®Google Scholar
• Kesecioglu J, Beale R, Stewart TE, et al. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2009;180(10):989–994.
   PubMed Web of Science ®Google Scholar
• Spragg RG, Taut FJH, Lewis JF, et al. Recombinant surfactant protein C–based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med. 2011;183(8):1055–1061.
   PubMed Web of Science ®Google Scholar
• Lewis SR, Pritchard MW, Thomas CM, et al. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev. 2019;7:CD004477.
   PubMedGoogle Scholar
• Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6(1):e000420.
   PubMed Web of Science ®Google Scholar
• Bellingan G, Maksimow M, Howell DC, et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med. 2014;2(2):98–107.
   PubMed Web of Science ®Google Scholar
• Ranieri VM, Pettilä V, Karvonen MK, et al. Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome. JAMA. 2020;323(8):725.
   PubMed Web of Science ®Google Scholar
• Amrein K, Schnedl C, Holl A, et al. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency. JAMA. 2014;312(15):1520.
   PubMed Web of Science ®Google Scholar
• Parekh D, Dancer RCA, Scott A, et al. Vitamin D to prevent lung injury following esophagectomy—a randomized, placebo-controlled trial*. Crit Care Med. 2018;46(12):e1128–e1135.
   PubMed Web of Science ®Google Scholar
• Ginde A, Brower R, Caterino J, et al. Early high-dose Vitamin D 3 for critically Ill, Vitamin D–deficient patients. N Engl J Med. 2019;381:2529–2540.
   PubMed Web of Science ®Google Scholar
• Teafatiller T, Agrawal S, De Robles G, et al. Vitamin C enhances antiviral functions of lung epithelial cells. Biomolecules. 2021;11(8):1148.
   PubMed Web of Science ®Google Scholar
• Fowler AA, Truwit JD, Hite RD, et al. Effect of Vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure. JAMA. 2019;322(13):1261.
   PubMed Web of Science ®Google Scholar
• Kor DJ, Carter RE, Park PK, et al. Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department. JAMA. 2016;315(22):2406.
   PubMed Web of Science ®Google Scholar
• Hamid U, Krasnodembskaya A, Fitzgerald M, et al. Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS. Thorax. 2017;72(11):971–980.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ding S, Li C, et al. Effects of N-acetylcysteine treatment in acute respiratory distress syndrome: a meta-analysis. Exp Ther Med. 2017;14(4):2863–2868.
   PubMed Web of Science ®Google Scholar
• Suter PM, Domenighetti G, Schaller M-D, et al. N-Acetylcysteine enhances recovery from acute lung injury in man. Chest. 1994;105(1):190–194.
   PubMed Web of Science ®Google Scholar
• Bernard GR, Wheeler AP, Arons MM, et al. A Trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest. 1997;112(1):164–172.
   PubMed Web of Science ®Google Scholar
• Domenighetti G, Suter PM, Schaller M-D, et al. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care. 1997;12(4):177–182.
   PubMed Web of Science ®Google Scholar
• Ortolani O, Conti A, De Gaudio AR, et al. Protective effects of N-acetylcisteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock. 2000;13(1):14–18.
   PubMed Web of Science ®Google Scholar
• Soltan-Sharifi MS, Mojtahedzadeh M, Najafi A, et al. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Hum Exp Toxicol. 2007;26(9):697–703.
   PubMed Web of Science ®Google Scholar
• Moradi M, Mojtahedzadeh M, Mandegari A, et al. The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI/ARDS patient treated with N-acetylcysteine. Respir Med. 2009;103(3):434–441.
   PubMed Web of Science ®Google Scholar
• Najafi A, Mojtahedzadeh M, Mahmoodpoor A, et al. Clinical research Effect of N-acetylcysteine on microalbuminuria in patients with acute respiratory distress syndrome. Arch Med Sci. 2009;5:408–414.
   Web of Science ®Google Scholar
• Bassford CR, Thickett DR, Perkins GD. The rise and fall of β-agonists in the treatment of ARDS. Crit Care. 2012;16(2):208.
   PubMed Web of Science ®Google Scholar
• Wright PE, Carmichael LC, Bernard GR. Effect of bronchodilators on lung mechanics in the Acute Respiratory Distress Syndrome (ARDS). Chest. 1994;106(5):1517–1523.
   PubMed Web of Science ®Google Scholar
• Perkins GD, McAuley DF, Thickett DR, et al. The β-Agonist Lung Injury Trial (BALTI). Am J Respir Crit Care Med. 2006;173(3):281–287.
   PubMed Web of Science ®Google Scholar
• Matthay M, Brower R, Carson S, et al. Randomized, placebo-controlled clinical trial of an aerosolized β 2 -agonist for treatment of acute lung injury. Am J Respir Crit Care Med. 2011;184:561–568.
   PubMed Web of Science ®Google Scholar
• Gates S, Perkins G, Lamb S, et al. Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome. Health Technol Assess (Rockv). 2013;17:1–87.
   Web of Science ®Google Scholar
• Festic E, Carr GE, Cartin-Ceba R, et al. Randomized clinical trial of a combination of an inhaled corticosteroid and beta agonist in patients at risk of developing the acute respiratory distress syndrome. Crit Care Med. 2017;45(5):798–805.
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Inoue T, Kyi M, et al. Effects of a neutrophil elastase inhibitor (ONO-5046) on acute pulmonary injury induced by Tumor Necrosis Factor Alpha (TNF α) and activated neutrophils in isolated perfused rabbit lungs. Am J Respir Crit Care Med. 1998;157(1):89–94.
   PubMed Web of Science ®Google Scholar
• Tamakuma S, Ogawa M, Aikawa N, et al. Relationship between neutrophil elastase and acute lung injury in humans. Pulm Pharmacol Ther. 2004;17(5):271–279.
   PubMed Web of Science ®Google Scholar
• Kadoi Y, Hinohara H, Kunimoto F, et al. Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome. Anesth Analg. 2004;99(3):872–877.
   PubMed Web of Science ®Google Scholar
• Zeiher BG, Artigas A, Vincent J-L, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32:1695–1702.
   PubMed Web of Science ®Google Scholar
• Endo S, Sato N, Yaegashi Y, et al. Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction. Res Commun Mol Pathol Pharmacol. 2006;119(1–6):53–65.
   PubMedGoogle Scholar
• Ryugo M, Sawa Y, Takano H, et al. Effect of a polymorphonuclear elastase inhibitor (Sivelestat Sodium) on acute lung injury after cardiopulmonary bypass: findings of a double-blind randomized study. Surg Today. 2006;36(4):321–326.
   PubMed Web of Science ®Google Scholar
• Pu S, Wang D, Liu D, et al. Effect of sivelestat sodium in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. BMC Pulm Med. 2017;17(1):148.
   PubMedGoogle Scholar
• Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome. Crit Care Med. 1998;26(1):15–23.
   PubMed Web of Science ®Google Scholar
• Adhikari NKJ, Dellinger RP, Lundin S, et al. Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity. Crit Care Med. 2014;42(2):404–412.
   PubMed Web of Science ®Google Scholar
• Michael J, Barton R, Saffle J, et al. Inhaled nitric oxide versus conventional therapy. Am J Respir Crit Care Med. 1998;157(5):1372–1380.
   PubMed Web of Science ®Google Scholar
• Troncy E, Collet J, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1998;157(5):1483–1488.
   PubMed Web of Science ®Google Scholar
• Lundin S, Mang H, Smithies M, et al. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. Intensive Care Med. 1999;25(9):911–919.
   PubMed Web of Science ®Google Scholar
• Paven D, Muret J, Beloucif S, et al. Inhaled nitric oxide, almitrine infusion, or their coadministration as a treatment of severe hypoxemic focal lung lesions. Anesthesiology. 1998;89(5):1157–1165.
   PubMed Web of Science ®Google Scholar
• Gebistorf F, Karam O, Wetterslev J, et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev. 2016;6:CD002787.
   Google Scholar
• Gerlach H, Keh D, Semmerow A, et al. Dose–response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome. Am J Respir Crit Care Med. 2003;167(7):1008–1015.
   PubMed Web of Science ®Google Scholar
• Park KJ, Lee YJ, Oh YJ, et al. Combined effects of inhaled nitric oxide and a recruitment maneuver in patients with acute respiratory distress syndrome. Yonsei Med J. 2003;44(2):219.
   PubMed Web of Science ®Google Scholar
• Taylor RW, Zimmerman J, Dellinger R, et al. Low-dose inhaled nitric oxide in patients with acute lung injury a randomized controlled trial. JAMA. 2004;291(13):1603.
   PubMed Web of Science ®Google Scholar
• Perrin G, Roch A, Michelet P, et al. Inhaled nitric oxide does not prevent pulmonary edema after lung transplantation measured by lung water content. Chest. 2006;129(4):1024–1030.
   PubMed Web of Science ®Google Scholar
• Ford HJ, Anderson WH, Wendlandt B, et al. Randomized, placebo-controlled trial of inhaled treprostinil for patients at risk for acute respiratory distress syndrome. Ann Am Thorac Soc. 2021;18(4):641–647.
   PubMed Web of Science ®Google Scholar
• Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153(3):991–996.
   PubMed Web of Science ®Google Scholar
• Liu L, Hu S, Shuai T, et al. Clinical effect of alprostadil in patients with septic shock associated with acute respiratory distress syndrome. Plamj. 2017;42.
   Google Scholar
• Vincent J-L, Brase R, Santman F, et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. 2001;27(10):1578–1583.
   PubMed Web of Science ®Google Scholar
• Gong MN, Thompson BT, Williams P, et al. Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med. 2005;33(6):1191–1198.
   PubMed Web of Science ®Google Scholar
• Iscimen R, Cartin-Ceba R, Yilmaz M, et al. Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study. Crit Care Med. 2008;36:1518–1522.
   PubMed Web of Science ®Google Scholar
• Honiden S, Gong MN. Diabetes, insulin, and development of acute lung injury. Crit Care Med. 2009;37(8):2455–2464.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu Z, Jiao W, et al. Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials. BMC Pulm Med. 2019;19(1):196.
   PubMed Web of Science ®Google Scholar
• Feng Y. Efficacy of statin therapy in patients with acute respiratory distress syndrome/acute lung injury: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2018;22(10):3190–3198.
   PubMed Web of Science ®Google Scholar
• Craig TR, Duffy MJ, Shyamsundar M, et al. A randomized clinical trial of hydroxymethylglutaryl– coenzyme A reductase inhibition for acute lung Injury (The HARP Study). Am J Respir Crit Care Med. 2011;183:620–626.
   PubMed Web of Science ®Google Scholar
• McAuley DF, Laffey JG, O’Kane CM, et al. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014;371:1695–1703.
   PubMed Web of Science ®Google Scholar
• Truwit J, Bernard G, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014;370:2191–2200.
   PubMed Web of Science ®Google Scholar
• Chen Y, Luo J, Jiang D, et al. Effect of ulinastatin on acute lung injury induced by severe heat stroke and its mechanism. Cochrane Libr. 2017;42:301–306.
   Google Scholar
• Ji M, Chen T, Wang B, et al. Effects of ulinastatin combined with mechanical ventilation on oxygen metabolism, inflammation and stress response and antioxidant capacity of ARDS. Exp Ther Med. 2018;15(6):4665–4670.
   PubMed Web of Science ®Google Scholar
• Grimaldi D, Durand A, Gleeson J, et al. Failure of statins in ARDS: the quest for the Holy Grail continues. Minerva Anestesiol. 2016;82(11):1230–1234.
   PubMed Web of Science ®Google Scholar
• Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15(1):39.
   PubMedGoogle Scholar
• Wick KD, Leligdowicz A, Zhuo H, et al. Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS. JCI Insight. 2021;6(12):e1488983.
   Web of Science ®Google Scholar
• Bellingan G, Jacono F, Bannard-Smith J, et al. Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial. Intensive Care Med. 2022;48(1):36–44.
   PubMed Web of Science ®Google Scholar
• Schmid B, Kredel M, Ullrich R, et al. Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate-to-severe ARDS—a randomized, placebo-controlled, double-blind trial. Trials. 2021;22(1):643.
   PubMed Web of Science ®Google Scholar
• Dixon B, Smith RJ, Campbell DJ, et al. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(4):360–372.
   PubMed Web of Science ®Google Scholar
• Christie JD, Vaslef S, Chang PK, et al. A randomized dose-escalation study of the safety and anti-inflammatory activity of the p38 mitogen-activated protein kinase inhibitor dilmapimod in severe trauma subjects at risk for acute respiratory distress syndrome. Crit Care Med. 2015;43(9):1859–1869.
   PubMed Web of Science ®Google Scholar
• Yang S, Dumitrescu TP. Population pharmacokinetics and pharmacodynamics modelling of dilmapimod in severe trauma subjects at risk for acute respiratory distress syndrome. Drugs R D. 2017;17(1):145–158.
   PubMed Web of Science ®Google Scholar
• Meng -S-S, Chang W, Lu Z-H, et al. Effect of surfactant administration on outcomes of adult patients in acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. BMC Pulm Med. 2019;19(1):9.
   PubMedGoogle Scholar
• Willson DF, Truwit JD, Conaway MR, et al. The adult calfactant in acute respiratory distress syndrome trial. Chest. 2015;148(2):356–364.
   PubMed Web of Science ®Google Scholar
• Barrese-Perez Y, Hidalgo-Sanchez A, Avila-Albuerne Y, et al. Pulmonary surfactant exogenous in adults with acute respiratory distress syndrome. Neumol Cir Torax. 2015;74:172–178.
   Google Scholar
• Frossard JL, Saluja AK, Mach N, et al. In vivo evidence for the role of GM-CSF as a mediator in acute pancreatitis-associated lung injury. Am J Physiol Cell Mol Physiol. 2002;283(3):L541–L548.
   PubMed Web of Science ®Google Scholar
• Paine R, Standiford TJ, Dechert RE, et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med. 2012;40(1):90–97.
   PubMed Web of Science ®Google Scholar
• Liu B, Yin Q, Chen Y-X, et al. Role of Presepsin (sCD14-ST) and the CURB65 scoring system in predicting severity and outcome of community-acquired pneumonia in an emergency department. Respir Med. 2014;108(8):1204–1213.
   PubMed Web of Science ®Google Scholar
• Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21(1):234.
   PubMedGoogle Scholar
• Morelli A, Teboul J-L, Maggiore SM, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med. 2006;34(9):2287–2293.
   PubMed Web of Science ®Google Scholar
• Ards Network Authors for the Ards Network T. The ARDS Network Authors for the ARDS network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome. JAMA. 2000;283(15):1995.
   PubMed Web of Science ®Google Scholar
• The ARDS Clinical Trials Network. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2002;30(1):1–6.
   PubMed Web of Science ®Google Scholar
• Granholm A, Munch MW, Myatra SN, et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Med. 2022;48(1):45–55.
   PubMed Web of Science ®Google Scholar
• Russell L, Uhre KR, Lindgaard ALS, et al. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia. JAMA. 2021;326(18):1807.
   PubMed Web of Science ®Google Scholar
• The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 — preliminary Report. N Engl J Med. 2020;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• The RECOVERY collaborative group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645.
   PubMed Web of Science ®Google Scholar
• REMAP-CAP investigators. Interleukin-6 receptor antagonists in critically Ill Patients with Covid-19. N Engl J Med. 2021;384(16):1491–1502.
   PubMed Web of Science ®Google Scholar
• Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407–1418.
   PubMed Web of Science ®Google Scholar
• WHO. WHO Therapeutics and COVID-19: living guideline. 7 December. 2021.
   Google Scholar
• Lamontagne F, Agoritsas T, Siemieniuk R, et al. A living WHO guideline on drugs to prevent covid-19. BMJ. 2021;372:526.
   Google Scholar
• Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021;373:949.
   Google Scholar
• Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406–415.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807.
   PubMed Web of Science ®Google Scholar
• Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. Can Med Assoc J. 2022;194(7):E242–E251.
   PubMed Web of Science ®Google Scholar
• Lingas G, Néant N, Gaymard A, et al. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. J Antimicrob Chemother. 2022;77(5):1404–1412.
   PubMed Web of Science ®Google Scholar
• EMA. EMA recommends approval for use of Kineret in adults with COVID-19 [Internet]. European Medicines Agency Science & Medicine Health; 2021 [cited 2022 Jan 5]. Available from: https://www.ema.europa.eu/en/news/ema-recommends-approval-use-kineret-adults-covid-19
   Google Scholar
• Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752–1760.
   PubMed Web of Science ®Google Scholar
• Tharaux P-L, Pialoux G, Pavot A, et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021;9:295–304.
   PubMed Web of Science ®Google Scholar
• Caricchio R, Abbate A, Gordeev I, et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19. JAMA. 2021;326(3):230.
   PubMed Web of Science ®Google Scholar
• NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. NIH COVID-19 Treat. Guidel; 2021 [cited 2022 Jan 5]. Available from: https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new
   Google Scholar
• Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2021;27:2012–2024.
   PubMed Web of Science ®Google Scholar
• Devos T, Van Thillo Q, Compernolle V, et al. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: dawn-plasma. Eur Respir J. 2022;59(2):2101724.
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from covid-19. N Engl J Med. 2021;384(11):1015–1027.
   PubMed Web of Science ®Google Scholar
• Janiaud P, Hemkens LG, Ioannidis JPA. Challenges and lessons learned from COVID-19 Trials: should we be doing clinical trials differently? Can J Cardiol. 2021;37(9):1353–1364.
   PubMed Web of Science ®Google Scholar
• Park JJH, Mogg R, Smith GE, et al. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob Heal. 2021;9(5):e711–e720.
   PubMed Web of Science ®Google Scholar
• Landoni G, Piemonti L, Monforte AD, et al. A multicenter phase 2 randomized controlled study on the efficacy and safety of reparixin in the treatment of hospitalized patients with COVID-19 pneumonia. Infect Dis Ther. 2022;26:1–16.
   Google Scholar
• Laffey JG, Kavanagh BP. FIfty years of Research in ARDS.Insight into acute respiratory distress syndrome. From models to patients. Am J Respir Crit Care Med. 2017;196(1):18–28.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Caironi P, Cressoni M, et al. Lung recruitment in patients with the acute respiratory distress syndrome. N Eng J Med. 2006;354(17):1775–1786.
   PubMed Web of Science ®Google Scholar
• Samanta RJ, Summers C. Translational research in intensive care Unit: novel approaches for drug development and personalized medicine. Semin Respir Crit Care Med. 2019;40(5):687–698.
   PubMed Web of Science ®Google Scholar
• Calfee CS, Eisner MD, Ware LB, et al. Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders*. Crit Care Med. 2007;35(10):2243–2250.
   PubMed Web of Science ®Google Scholar
• Luo L, Shaver CM, Zhao Z, et al. Clinical predictors of hospital mortality differ between direct and indirect ARDS. Chest. 2017;151(4):755–763.
   PubMed Web of Science ®Google Scholar
• Calfee CS, Janz DR, Bernard GR, et al. Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. Chest. 2015;147(6):1539–1548.
   PubMed Web of Science ®Google Scholar
• Du M, Garcia JGN, Christie JD, et al. Integrative omics provide biological and clinical insights into acute respiratory distress syndrome. Intensive Care Med. 2021;47(7):761–771.
   PubMed Web of Science ®Google Scholar
• Battaglini D, Lopes-Pacheco M, Castro-Faria-Neto HC, et al. Laboratory biomarkers for diagnosis and prognosis in COVID-19. Front Immunol. 2022;13:857573.
   PubMedGoogle Scholar
• Ware LB, Matthay MA, Mebazaa A. Designing an ARDS trial for 2020 and beyond: focus on enrichment strategies. Intensive Care Med. 2020;46(12):2153–2156.
   PubMed Web of Science ®Google Scholar
• Neto AS, Barbas CSV, Simonis FD, et al. Epidemiological characteristics, practice of ventilation, and clinical outcome in patients at risk of acute respiratory distress syndrome in intensive care units from 16 countries (PRoVENT): an international, multicentre, prospective study. Lancet Respir Med. 2016;4(11):882–893.
   PubMed Web of Science ®Google Scholar
• Wang CY, Calfee CS, Paul DW, et al. One-year mortality and predictors of death among hospital survivors of acute respiratory distress syndrome. Intensive Care Med. 2014;40(3):388–396.
   PubMed Web of Science ®Google Scholar
• Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3(1):24–32.
   PubMed Web of Science ®Google Scholar
• Liu KD, Wilson JG, Zhuo H, et al. Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Ann Intensive Care. 2014;4(1):22.
   PubMedGoogle Scholar
• Prescott HC, Calfee CS, Thompson BT, et al., Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med. 2016;194(2):147–155.
   PubMed Web of Science ®Google Scholar
• Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest. 2010;137(2):288–296.
   PubMed Web of Science ®Google Scholar
• Mullard A. RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape. Nat Rev Drug Discov. 2021;20(5):336–337.
   PubMed Web of Science ®Google Scholar
• Millar JE, Wildi K, Bartnikowski N, et al. Characterizing preclinical sub‐phenotypic models of acute respiratory distress syndrome: an experimental ovine study. Physiol Rep. 2021;9(19):e15048.
   PubMed Web of Science ®Google Scholar
• Zhai R, Bonda WLM, Matute-Bello G, et al. From preclinical to clinical models of acute respiratory distress syndrome. Signa Vitae. 2021;18:3–14.
   Web of Science ®Google Scholar
• Spagnolo F, Ghiorzo P, and Orgiano L, et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther. 2015;8:157–168.
   PubMed Web of Science ®Google Scholar